---
document_datetime: 2025-12-02 06:43:33
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/telmisartan-teva-pharma.html
document_name: telmisartan-teva-pharma.html
version: success
processing_time: 0.6671172
conversion_datetime: 2025-12-28 20:15:22.140135
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Telmisartan Teva Pharma

[RSS](/en/individual-human-medicine.xml/65864)

##### Authorised

This medicine is authorised for use in the European Union

telmisartan Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Telmisartan Teva Pharma](#news-on)
- [More information on Telmisartan Teva Pharma](#more-information-on-telmisartan-teva-pharma-543)
- [More information on Telmisartan Teva Pharma](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Telmisartan Teva Pharma. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Telmisartan Teva Pharma.

Expand section

Collapse section

## What is Telmisartan Teva Pharma?

Telmisartan Teva Pharma is a medicine that contains the active substance telmisartan. It is available as tablets (20 mg, 40 mg and 80 mg).

Telmisartan Teva Pharma is a 'generic medicine'. This means that Telmisartan Teva Pharma is similar to a 'reference medicine' already authorised in the European Union (EU) called Micardis.

## What is Telmisartan Teva Pharma used for?

Telmisartan Teva Pharma is used to treat essential hypertension (high blood pressure) in adults. 'Essential' means that the hypertension has no obvious cause.

Telmisartan Teva Pharma is also used to prevent cardiovascular problems (problems with the heart and blood vessels) such as heart attacks or strokes. It is used in patients who have had problems due to blood clots in the past (such as heart disease, a stroke or artery disease) or who have type 2 diabetes that has damaged an organ (such as the eyes, heart or kidneys).

The medicine can only be obtained with a prescription.

## How is Telmisartan Teva Pharma used?

For the treatment of hypertension, the usual recommended dose of Telmisartan Teva Pharma is 40 mg once a day, but some patients may benefit from using a 20-mg dose. If the target blood pressure is not reached, the dose can be increased to 80 mg, or another medicine for hypertension can be added, such as hydrochlorothiazide.

For the prevention of cardiovascular problems, the recommended dose is 80 mg once a day. The doctor should monitor the patient's blood pressure closely when starting Telmisartan Teva Pharma, and may decide to adjust the patient's blood pressure-lowering medication. Patients with severely reduced kidney function should receive a lower starting dose of 20 mg once a day. Patients with mild or moderately reduced liver function should not receive doses higher than 40 mg a day.

## How does Telmisartan Teva Pharma work?

The active substance in Telmisartan Teva Pharma, telmisartan, is an 'angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II. Angiotensin II is a powerful vasoconstrictor (a substance that narrows blood vessels). By blocking the receptors to which angiotensin II normally attaches, telmisartan stops the hormone having an effect, allowing the blood vessels to widen. This allows the blood pressure to drop, reducing the risks associated with high blood pressure, such as having a heart attack or stroke. It also allows the heart to pump blood more easily, which can help to reduce the risk of future cardiovascular problems.

## How has Telmisartan Teva Pharma been studied?

Because Telmisartan Teva Pharma is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Micardis. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefits and risks of Telmisartan Teva Pharma?

Because Telmisartan Teva Pharma is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why has Telmisartan Teva Pharma been approved?

The CHMP concluded that, in accordance with EU requirements, Telmisartan Teva Pharma has been shown to have comparable quality and to be bioequivalent to Micardis. Therefore, the CHMP's view was that, as for Micardis, the benefit outweighs the identified risk. The Committee recommended that Telmisartan Teva Pharma be given marketing authorisation.

## Other information about Telmisartan Teva Pharma:

The European Commission granted a marketing authorisation valid throughout the EU for Telmisartan Teva Pharma on 3 October 2011.

For more information about treatment with Telmisartan Teva Pharma, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Telmisartan Teva Pharma : EPAR - Summary for the public

Reference Number: EMA/684956/2011

English (EN) (79.9 KB - PDF)

**First published:** 18/10/2011

**Last updated:** 19/06/2015

[View](/en/documents/overview/telmisartan-teva-pharma-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-67)

български (BG) (109.35 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

19/06/2015

[View](/bg/documents/overview/telmisartan-teva-pharma-epar-summary-public_bg.pdf)

español (ES) (104.13 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

19/06/2015

[View](/es/documents/overview/telmisartan-teva-pharma-epar-summary-public_es.pdf)

čeština (CS) (105.35 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

19/06/2015

[View](/cs/documents/overview/telmisartan-teva-pharma-epar-summary-public_cs.pdf)

dansk (DA) (81.4 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

19/06/2015

[View](/da/documents/overview/telmisartan-teva-pharma-epar-summary-public_da.pdf)

Deutsch (DE) (105.97 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

19/06/2015

[View](/de/documents/overview/telmisartan-teva-pharma-epar-summary-public_de.pdf)

eesti keel (ET) (80.29 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

19/06/2015

[View](/et/documents/overview/telmisartan-teva-pharma-epar-summary-public_et.pdf)

ελληνικά (EL) (110.92 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

19/06/2015

[View](/el/documents/overview/telmisartan-teva-pharma-epar-summary-public_el.pdf)

français (FR) (82.83 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

19/06/2015

[View](/fr/documents/overview/telmisartan-teva-pharma-epar-summary-public_fr.pdf)

hrvatski (HR) (92.26 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

19/06/2015

[View](/hr/documents/overview/telmisartan-teva-pharma-epar-summary-public_hr.pdf)

italiano (IT) (81.58 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

19/06/2015

[View](/it/documents/overview/telmisartan-teva-pharma-epar-summary-public_it.pdf)

latviešu valoda (LV) (100.94 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

19/06/2015

[View](/lv/documents/overview/telmisartan-teva-pharma-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (102.46 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

19/06/2015

[View](/lt/documents/overview/telmisartan-teva-pharma-epar-summary-public_lt.pdf)

magyar (HU) (102.43 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

19/06/2015

[View](/hu/documents/overview/telmisartan-teva-pharma-epar-summary-public_hu.pdf)

Malti (MT) (103.87 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

19/06/2015

[View](/mt/documents/overview/telmisartan-teva-pharma-epar-summary-public_mt.pdf)

Nederlands (NL) (81.5 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

19/06/2015

[View](/nl/documents/overview/telmisartan-teva-pharma-epar-summary-public_nl.pdf)

polski (PL) (106.29 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

19/06/2015

[View](/pl/documents/overview/telmisartan-teva-pharma-epar-summary-public_pl.pdf)

português (PT) (81.28 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

19/06/2015

[View](/pt/documents/overview/telmisartan-teva-pharma-epar-summary-public_pt.pdf)

română (RO) (101.71 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

19/06/2015

[View](/ro/documents/overview/telmisartan-teva-pharma-epar-summary-public_ro.pdf)

slovenčina (SK) (105.7 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

19/06/2015

[View](/sk/documents/overview/telmisartan-teva-pharma-epar-summary-public_sk.pdf)

slovenščina (SL) (95.82 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

19/06/2015

[View](/sl/documents/overview/telmisartan-teva-pharma-epar-summary-public_sl.pdf)

Suomi (FI) (80.68 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

19/06/2015

[View](/fi/documents/overview/telmisartan-teva-pharma-epar-summary-public_fi.pdf)

svenska (SV) (79.99 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

19/06/2015

[View](/sv/documents/overview/telmisartan-teva-pharma-epar-summary-public_sv.pdf)

## Product information

Telmisartan Teva Pharma : EPAR - Product Information

English (EN) (522.14 KB - PDF)

**First published:** 18/10/2011

**Last updated:** 26/10/2021

[View](/en/documents/product-information/telmisartan-teva-pharma-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-26)

български (BG) (623.39 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/bg/documents/product-information/telmisartan-teva-pharma-epar-product-information_bg.pdf)

español (ES) (522.19 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/es/documents/product-information/telmisartan-teva-pharma-epar-product-information_es.pdf)

čeština (CS) (574.64 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/cs/documents/product-information/telmisartan-teva-pharma-epar-product-information_cs.pdf)

dansk (DA) (509.87 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/da/documents/product-information/telmisartan-teva-pharma-epar-product-information_da.pdf)

Deutsch (DE) (564.92 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/de/documents/product-information/telmisartan-teva-pharma-epar-product-information_de.pdf)

eesti keel (ET) (521.82 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/et/documents/product-information/telmisartan-teva-pharma-epar-product-information_et.pdf)

ελληνικά (EL) (638.85 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/el/documents/product-information/telmisartan-teva-pharma-epar-product-information_el.pdf)

français (FR) (536.21 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/fr/documents/product-information/telmisartan-teva-pharma-epar-product-information_fr.pdf)

hrvatski (HR) (597.02 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/hr/documents/product-information/telmisartan-teva-pharma-epar-product-information_hr.pdf)

íslenska (IS) (478.41 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/is/documents/product-information/telmisartan-teva-pharma-epar-product-information_is.pdf)

italiano (IT) (509.86 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/it/documents/product-information/telmisartan-teva-pharma-epar-product-information_it.pdf)

latviešu valoda (LV) (610.42 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/lv/documents/product-information/telmisartan-teva-pharma-epar-product-information_lv.pdf)

lietuvių kalba (LT) (654.07 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/lt/documents/product-information/telmisartan-teva-pharma-epar-product-information_lt.pdf)

magyar (HU) (583.78 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/hu/documents/product-information/telmisartan-teva-pharma-epar-product-information_hu.pdf)

Malti (MT) (703.95 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/mt/documents/product-information/telmisartan-teva-pharma-epar-product-information_mt.pdf)

Nederlands (NL) (521.3 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/nl/documents/product-information/telmisartan-teva-pharma-epar-product-information_nl.pdf)

norsk (NO) (507.57 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/no/documents/product-information/telmisartan-teva-pharma-epar-product-information_no.pdf)

polski (PL) (603.22 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/pl/documents/product-information/telmisartan-teva-pharma-epar-product-information_pl.pdf)

português (PT) (539.44 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/pt/documents/product-information/telmisartan-teva-pharma-epar-product-information_pt.pdf)

română (RO) (582.05 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/ro/documents/product-information/telmisartan-teva-pharma-epar-product-information_ro.pdf)

slovenčina (SK) (562.76 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/sk/documents/product-information/telmisartan-teva-pharma-epar-product-information_sk.pdf)

slovenščina (SL) (543.31 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/sl/documents/product-information/telmisartan-teva-pharma-epar-product-information_sl.pdf)

Suomi (FI) (512.61 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/fi/documents/product-information/telmisartan-teva-pharma-epar-product-information_fi.pdf)

svenska (SV) (511.58 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/sv/documents/product-information/telmisartan-teva-pharma-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IAIN/0024 08/10/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Telmisartan Teva Pharma : EPAR - All Authorised presentations

English (EN) (50.78 KB - PDF)

**First published:** 18/10/2011

**Last updated:** 26/10/2021

[View](/en/documents/all-authorised-presentations/telmisartan-teva-pharma-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-963)

български (BG) (98.29 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/bg/documents/all-authorised-presentations/telmisartan-teva-pharma-epar-all-authorised-presentations_bg.pdf)

español (ES) (74.13 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/es/documents/all-authorised-presentations/telmisartan-teva-pharma-epar-all-authorised-presentations_es.pdf)

čeština (CS) (83.49 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/cs/documents/all-authorised-presentations/telmisartan-teva-pharma-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (71.33 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/da/documents/all-authorised-presentations/telmisartan-teva-pharma-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (75.46 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/de/documents/all-authorised-presentations/telmisartan-teva-pharma-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (52.47 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/et/documents/all-authorised-presentations/telmisartan-teva-pharma-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (93.42 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/el/documents/all-authorised-presentations/telmisartan-teva-pharma-epar-all-authorised-presentations_el.pdf)

français (FR) (73.39 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/fr/documents/all-authorised-presentations/telmisartan-teva-pharma-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (68.97 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/hr/documents/all-authorised-presentations/telmisartan-teva-pharma-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (75.01 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/is/documents/all-authorised-presentations/telmisartan-teva-pharma-epar-all-authorised-presentations_is.pdf)

italiano (IT) (50.8 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/it/documents/all-authorised-presentations/telmisartan-teva-pharma-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (91.97 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/lv/documents/all-authorised-presentations/telmisartan-teva-pharma-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (97.37 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/lt/documents/all-authorised-presentations/telmisartan-teva-pharma-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (93.2 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/hu/documents/all-authorised-presentations/telmisartan-teva-pharma-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (73.72 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/mt/documents/all-authorised-presentations/telmisartan-teva-pharma-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (71.23 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/nl/documents/all-authorised-presentations/telmisartan-teva-pharma-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (74.23 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/no/documents/all-authorised-presentations/telmisartan-teva-pharma-epar-all-authorised-presentations_no.pdf)

polski (PL) (91.27 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/pl/documents/all-authorised-presentations/telmisartan-teva-pharma-epar-all-authorised-presentations_pl.pdf)

português (PT) (76.09 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/pt/documents/all-authorised-presentations/telmisartan-teva-pharma-epar-all-authorised-presentations_pt.pdf)

română (RO) (80.12 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/ro/documents/all-authorised-presentations/telmisartan-teva-pharma-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (71.24 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/sk/documents/all-authorised-presentations/telmisartan-teva-pharma-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (81.86 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/sl/documents/all-authorised-presentations/telmisartan-teva-pharma-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (54.7 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/fi/documents/all-authorised-presentations/telmisartan-teva-pharma-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (72.22 KB - PDF)

**First published:**

18/10/2011

**Last updated:**

26/10/2021

[View](/sv/documents/all-authorised-presentations/telmisartan-teva-pharma-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Telmisartan Teva Pharma Active substance telmisartan International non-proprietary name (INN) or common name telmisartan Therapeutic area (MeSH) Hypertension Anatomical therapeutic chemical (ATC) code C09CA07

### Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

### Therapeutic indication

Treatment of essential hypertension in adults.

## Authorisation details

EMA product number EMEA/H/C/002511

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Teva B.V.

Swensweg 5

Opinion adopted 21/07/2011 Marketing authorisation issued 03/10/2011 Revision 10

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Telmisartan Teva Pharma : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (169.57 KB - PDF)

**First published:** 09/08/2012

**Last updated:** 26/10/2021

[View](/en/documents/procedural-steps-after/telmisartan-teva-pharma-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Telmisartan Teva Pharma-H-C-2511-A31-0006 : Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC ...

English (EN) (48.81 KB - PDF)

**First published:** 26/09/2014

**Last updated:** 26/09/2014

[View](/en/documents/scientific-conclusion/telmisartan-teva-pharma-h-c-2511-a31-0006-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac_en.pdf)

[Other languages (22)](#file-language-dropdown-470)

български (BG) (87.49 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/bg/documents/scientific-conclusion/telmisartan-teva-pharma-h-c-2511-a31-0006-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac_bg.pdf)

español (ES) (50.51 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/es/documents/scientific-conclusion/telmisartan-teva-pharma-h-c-2511-a31-0006-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac_es.pdf)

čeština (CS) (82.81 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/cs/documents/scientific-conclusion/telmisartan-teva-pharma-h-c-2511-a31-0006-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac_cs.pdf)

dansk (DA) (49.01 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/da/documents/scientific-conclusion/telmisartan-teva-pharma-h-c-2511-a31-0006-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac_da.pdf)

Deutsch (DE) (53.54 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/de/documents/scientific-conclusion/telmisartan-teva-pharma-h-c-2511-a31-0006-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac_de.pdf)

eesti keel (ET) (50.6 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/et/documents/scientific-conclusion/telmisartan-teva-pharma-h-c-2511-a31-0006-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac_et.pdf)

ελληνικά (EL) (89.54 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/el/documents/scientific-conclusion/telmisartan-teva-pharma-h-c-2511-a31-0006-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac_el.pdf)

français (FR) (51.91 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/fr/documents/scientific-conclusion/telmisartan-teva-pharma-h-c-2511-a31-0006-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac_fr.pdf)

hrvatski (HR) (80.12 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/hr/documents/scientific-conclusion/telmisartan-teva-pharma-h-c-2511-a31-0006-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac_hr.pdf)

italiano (IT) (51.13 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/it/documents/scientific-conclusion/telmisartan-teva-pharma-h-c-2511-a31-0006-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac_it.pdf)

latviešu valoda (LV) (81.63 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/lv/documents/scientific-conclusion/telmisartan-teva-pharma-h-c-2511-a31-0006-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac_lv.pdf)

lietuvių kalba (LT) (82.54 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/lt/documents/scientific-conclusion/telmisartan-teva-pharma-h-c-2511-a31-0006-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac_lt.pdf)

magyar (HU) (68.7 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/hu/documents/scientific-conclusion/telmisartan-teva-pharma-h-c-2511-a31-0006-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac_hu.pdf)

Malti (MT) (84.23 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/mt/documents/scientific-conclusion/telmisartan-teva-pharma-h-c-2511-a31-0006-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac_mt.pdf)

Nederlands (NL) (49.82 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/nl/documents/scientific-conclusion/telmisartan-teva-pharma-h-c-2511-a31-0006-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac_nl.pdf)

polski (PL) (83.62 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/pl/documents/scientific-conclusion/telmisartan-teva-pharma-h-c-2511-a31-0006-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac_pl.pdf)

português (PT) (49.74 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/pt/documents/scientific-conclusion/telmisartan-teva-pharma-h-c-2511-a31-0006-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac_pt.pdf)

română (RO) (88.19 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/ro/documents/scientific-conclusion/telmisartan-teva-pharma-h-c-2511-a31-0006-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac_ro.pdf)

slovenčina (SK) (81.5 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/sk/documents/scientific-conclusion/telmisartan-teva-pharma-h-c-2511-a31-0006-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac_sk.pdf)

slovenščina (SL) (79.79 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/sl/documents/scientific-conclusion/telmisartan-teva-pharma-h-c-2511-a31-0006-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac_sl.pdf)

Suomi (FI) (49.15 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/fi/documents/scientific-conclusion/telmisartan-teva-pharma-h-c-2511-a31-0006-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac_fi.pdf)

svenska (SV) (50.18 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/sv/documents/scientific-conclusion/telmisartan-teva-pharma-h-c-2511-a31-0006-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac_sv.pdf)

Telmisartan Teva Pharma-H-C-2511-A31-0006 : EPAR - Assessment Report - Article 31

Adopted

Reference Number: EMA/PRAC/294920/2014

English (EN) (301.42 KB - PDF)

**First published:** 26/09/2014

**Last updated:** 26/09/2014

[View](/en/documents/variation-report/telmisartan-teva-pharma-h-c-2511-a31-0006-epar-assessment-report-article-31_en.pdf)

## Initial marketing authorisation documents

Telmisartan Teva Pharma : EPAR - Public assessment report

Adopted

Reference Number: EMA/777686/2011

English (EN) (223.73 KB - PDF)

**First published:** 18/10/2011

**Last updated:** 18/10/2011

[View](/en/documents/assessment-report/telmisartan-teva-pharma-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Telmisartan Teva Pharma

Adopted

Reference Number: EMA/CHMP/522766/2011

English (EN) (60.63 KB - PDF)

**First published:** 22/07/2011

**Last updated:** 22/07/2011

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-telmisartan-teva-pharma_en.pdf)

#### News on Telmisartan Teva Pharma

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2013](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-13-16-may-2013) 17/05/2013

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 October 2011](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-october-2011) 21/10/2011

[European Medicines Agency concludes that benefit-risk balance of angiotensin-II-receptor antagonists remains positive](/en/news/european-medicines-agency-concludes-benefit-risk-balance-angiotensin-ii-receptor-antagonists-remains-positive) 20/10/2011

#### More information on Telmisartan Teva Pharma

- [Renin-angiotensin-system (RAS)-acting agents: Article-31 referral](/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents)

Questions and answers on the review of angiotensin-II-receptor antagonists and the risk of cancer

Reference Number: EMA/CHMP/834168/2011

English (EN) (511.41 KB - PDF)

**First published:** 20/10/2011

**Last updated:** 11/05/2017

[View](/en/documents/opinion-any-scientific-matter/questions-answers-review-angiotensin-ii-receptor-antagonists-risk-cancer_en.pdf)

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### More information on Telmisartan Teva Pharma

- [Renin-angiotensin-system (RAS)-acting agents - referral](/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 26/10/2021

## Share this page

[Back to top](#main-content)